(Q44178087)

English

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design

scientific article published in October 2002

Statements

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design (English)
Raffaella Bitossi
Gabriella Gorzegno
Palmiro Alquati
Andrea De Matteis
Francesco Nuzzo
Giorgio Giardina
Saverio Danese
Mario De Lena
Vito Lorusso
Antonio Farris
Maria Giuseppa Sarobba
Enza DeFabiani
Giorgio Bonazzi
Federico Castiglione
Cesare Bumma
Gregorio Moro
Epirubicin-Lonidamine Group, Orbassano, Torino, Italy
1 October 2002
4150-4159

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit